# Teriparatide for severe osteoporosis.

> PubMed lists PMID 14742769 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2003-12-30 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-14742769-teriparatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-14742769-teriparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-14742769-teriparatide-v1.json
- Content SHA-256: `aba6b705876db2edf5904380ebbb82be1d9ac7d0a6b2a8f8684a0e61255741c3`

## Claims and source pins

### Headline

Teriparatide for severe osteoporosis. ([`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`](#source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b))

### Summary

PubMed lists PMID 14742769 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2003-12-30 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`](#source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b))

### Paragraph 1

PubMed lists PMID 14742769 in The Annals of pharmacotherapy as Journal Article, Review, with publication-date metadata of 2003-12-30 (day precision). PeptideScanner associated the retained record with the identity slug teriparatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`](#source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`](#source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b))

## Sources

<a id="source-pubmed-observation-pmid-14742769-2013-11-21-5d080718744b"></a>
- **Teriparatide for severe osteoporosis. · retained source version 1:2013-11-21:current:5d080718744b8cd30dc5f6f18f0e1adc732449dd2e212c9737105764ae577a26** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/14742769/) (`pubmed-observation-pmid-14742769-2013-11-21-5d080718744b`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Teriparatide for severe osteoporosis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-14742769-teriparatide-v1.json SHA-256: aba6b705876db2edf5904380ebbb82be1d9ac7d0a6b2a8f8684a0e61255741c3.